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Abstract 
      The immunoglobulin superfamily (IgSF) comprises
the immunoglobulins (IG) and T cell receptors (TR) 
involved in antigen recognition, and also a great 
number of proteins other than IG and TR that are 
involved in many different functions (in ligand-
receptor interactions in development, differentiation, 
activation, adhesion, regulation, etc.). The IgSF proteins 
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are  defined  by having  at  least        one immunoglobulin-like (Ig-like) domain. 
Despite a large divergence in the amino acid sequences, the Ig-like domains 
share the IG structural fold which typically consists of about one hundred 
amino acids in antiparallel beta strands, linked by beta turns or loops, and 
located on two layers maintained by a disulfide bridge. The number of 
antiparallel beta strands defines two sets: 9 strands for the V-set (which 
comprises the V-DOMAINs of the IG and TR, and the V-LIKE-DOMAINs of 
the IgSF proteins other than the IG or TR) and 7 strands for the C-set (which 
comprises the C-DOMAINs of the IG and TR, and the C-LIKE-DOMAINs of 
the IgSF proteins other than the IG or TR). IMGT, the international 
ImMunoGeneTics information system® (http://imgt.cines.fr), has set up a 
unique numbering system which takes into account the structural features of 
the Ig-like domains. In this paper, we describe the IMGT Scientific chart rules 
for the description of the IgSF V-set and C-set domains, that are applicable for 
the sequence and structure analysis, whatever the species, the IgSF protein or 
the chain type. We present examples of 2D graphical representations (IMGT 
Colliers de Perles) based on the IMGT unique numbering, that are particularly 
useful for the visualization and comparison of the positions of mutations and 
polymorphisms in the Ig-like domains. 
 
Introduction 
  IMGT, the international ImMunoGeneTics information system
® 
(http://imgt.cines.fr) [1] is a high quality integrated knowledge resource 
specializing in immunoglobulins (IG), T cell receptors (TR), major 
histocompatibility complex (MHC), and related proteins of the immune system 
(RPI) of human and other vertebrates [2-12]. IMGT provides a common access 
to expertly annotated data on the genome, proteome, genetics and structure of 
the IG, TR, MHC and RPI, based on the IMGT Scientific chart and IMGT-
ONTOLOGY [13]. The IMGT standardized description of mutations, allelic 
polymorphisms, 2D and 3D structure representations, is based on the IMGT 
unique numbering [14-17]. The IMGT unique numbering is used for the IG 
and TR variable (V-DOMAIN) and constant domain (C-DOMAIN) of all 
jawed vertebrates whatever the species, the antigen receptor, or the chain type 
[18-35]. The IMGT unique numbering led to the first complete description of 
the human IG and TR genes and alleles [18,19], the standardized 2D graphical 
representations or IMGT Colliers de Perles [16,17,34,36], the standardized 
definition of the framework (FR-IMGT) and complementarity-determining-
regions (CDR-IMGT) of the V-DOMAINs [16] and the description of the 
strands and loops of the C-DOMAINs [17]. The many advantages of the IMGT 
unique numbering naturally led us to extend it to members of the 
immunoglobulin superfamily (IgSF) other than IG or TR [37]. Indeed, the 
IgSF not only comprises the IG and TR involved in antigen recognition, but IMGT standardization for IgSF domains    113 
also a great number of proteins that are involved in many different functions 
(in ligand-receptor interactions in development, differentiation, activation, 
adhesion, regulation, etc.) [38]. The common feature of the IgSF proteins is to 
have at least one immunoglobulin-like (Ig-like) domain [37-41]. Despite a 
large divergence in the amino acid sequences, the Ig-like domains share the IG 
structural fold which typically consists of about one hundred amino acids in 
antiparallel beta strands, linked by beta turns or loops, and located on two 
layers maintained by a disulfide bridge. The number of antiparallel beta strands 
defines two sets: 9 strands for the V-set (which comprises the V-DOMAINs of 
the IG and TR, and the V-LIKE-DOMAINs of the IgSF proteins other than the 
IG or TR) [16], and 7 strands for the C-set (which comprises the C-DOMAINs 
of the IG and TR, and the C-LIKE-DOMAINs of the IgSF proteins other than 
the IG or TR) [17]. By taking into account the structural features of the Ig-like 
domains, the IMGT unique numbering [14-17] and its graphical 
representations, the IMGT Colliers de Perles [34,36,37], allow to fill in the gap 
between linear amino acid sequences and three-dimensional (3D) structures.  
  In this paper, we describe the IMGT Scientific chart rules for the 
description of the IgSF V-set and C-set domains, which are applicable for the 
sequence and structure analysis, whatever the species, the IgSF protein or the 
chain type. We present examples of IMGT Colliers de Perles based on the 
IMGT unique numbering. This standardization is particularly useful in the 
absence of 3D structural data, for the visualization and comparison of mutation 
and polymorphism positions in the Ig-like domains.  
 
1. IMGT Colliers de Perles for V-LIKE-DOMAIN 
  The IMGT Colliers de Perles for V-LIKE-DOMAIN is based on the IMGT 
unique numbering for V-DOMAIN and V-LIKE-DOMAIN [16]. Indeed, the 
3D structure of a V-LIKE-DOMAIN is very similar to that of an IG and TR V-
DOMAIN (Fig. 1). Both domain types are made of 9 antiparallel beta strands 
(A, B, C, C’, C”, D, E, F and G) linked by beta turns (AB, CC’, C”D, DE and 
EF) or loops (BC, C’C” and FG) forming a sandwich of two sheets (Figure 1). 
The sheets are closely packed against each other through hydrophobic 
interactions giving a hydrophobic core, and joined together by a disulfide 
bridge between strand B in the first sheet and strand F in the second sheet. In 
the IMGT unique numbering, the conserved amino acids always have the same 
position, for instance cysteine 23 (1st-CYS), tryptophan 41 (CONSERVED-
TRP), conserved hydrophobic (leucine) 89, cysteine 104 (2nd-CYS). The 
hydrophobic amino acids of the framework regions are also found in conserved 
positions [14-17]. It is remarkable that the IG fold 3D structure has been 
conserved through evolution, despite the particularities of the IG and TR 
synthesis compared to the other proteins [18,19] and the sequence divergence 
of the IgSF domains. Indeed, the V-LIKE-DOMAIN is usually encoded by a Elodie Duprat et al.  114
 
 
Figure 1. Schematic representation of the V-DOMAIN and V-LIKE-DOMAIN (V-set) 
and C-DOMAIN and C-LIKE-DOMAIN (C-set). (A) Representation on one layer. (B) 
Representation on two layers. A double-headed arrow shows that the D strand of the C-
DOMAIN and C-LIKE-DOMAIN can be localized in sheet 1 (on the back) or in sheet 2 
(on the front) depending from the length of the CD transversal strand. 
 
unique exon, whereas the IG and TR V-DOMAIN results from the rearrangement 
of two (V, J) or   three (V, D, J) genes [18,19] (Figure 2). The V-LIKE-DOMAIN 
is usually, as   the IG and TR V-DOMAIN, the most N-terminal (and extracellular) IMGT standardization for IgSF domains    115 
A. IG and TR 
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Figure 2. Correspondence between domains and exons. (A) IG and TR, (B) IgSF other 
than IG and TR. Lengths of the domains and exons are in number of amino acids or 
codons, respectively. IMGT standardized labels are in capital letters and are described 
in the IMGT Scientific chart (http://imgt.cines.fr). (A) Homo  sapiens membrane IG 
gamma 1 heavy chain (IMGT/LIGM-DB M98324) as example of IG and TR. An IG or 
TR chain comprises two types of structural units: one V-DOMAIN and one (for the IG 
light chains and TR chains) or several (for the IG heavy chains) C-DOMAINs (CH1, 
CH2 and CH3). The unique V-DOMAIN (encoded by a rearranged V-J or V-D-J gene) 
of a IG or TR chain corresponds to the V-J-REGION or V-D-J-REGION, and is 
associated to a C-REGION encoded by the C-GENE [18, 19]. (B) Homo sapiens CD4 
(EMBL/GenBank/DDBJ NT_009759) as example of an IgSF protein other than IG or 
TR. The general organization of the IgSF other than IG and TR is more diverse and 
follows the modular shuffling between domains ranging from a unique V-LIKE-
DOMAIN or a unique C-LIKE-DOMAIN or to any combination of those domains [38]. 
 
domain of the chain. However, in contrast to the IG and TR V-DOMAIN 
which is always unique, the V-LIKE-DOMAIN may be present in several 
copies in the same chain and interspersed with C-LIKE-DOMAINs (Figure 2) 
or with domains of other superfamilies [39]. 
 
1.1 Strands and loops of the V-LIKE-DOMAINs 
  Three examples of V-LIKE-DOMAINs are shown in Figure 3: the myelin 
oligodendrocyte glycoprotein (MOG) [D], the carcinoembryonic antigen-related cell 
adhesion molecule 1 (CEACAM1) [D1] and the myelin protein zero (MPZ) [D]. Elodie Duprat et al.  116
Figure 3 
A.  Homo sapiens MOG [D] V-LIKE-DOMAIN 
     
 
B. Homo sapiens CEACAM1 [D1] V-LIKE-DOMAIN 
     
C. Homo sapiens MPZ [D] V-LIKE-DOMAIN 
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Figure 3. IMGT Colliers de Perles of V-LIKE-DOMAINs on one and two layers. (A) 
Homo sapiens MOG [D], (B) Homo sapiens CEACAM1 [D1], (C) Homo sapiens MPZ 
[D]. Amino acids are shown in the one-letter abbreviation. Position at which 
hydrophobic amino acids (hydropathy index with positive value: I, V, L, F, C, M, A) 
and tryptophan (W) are found in more than 50% of analysed sequences are shown in 
blue. All proline (P) are shown in yellow. The loops BC, C’C” and FG (corresponding 
to the CDR-IMGT) are limited by amino acids shown in squares (anchor positions), 
which belong to the neighbouring strands (FR-IMGT in V-DOMAINs). Arrows 
indicate the direction of the beta strands and their  different designations in 3D 
structures (from IMGT Repertoire, http://imgt.cines.fr). BC loops are represented in 
red, C'C" loops in orange and FG loops in purple. The IMGT Colliers de Perles on two 
layers (on the right hand) show, on the forefront, the GFCC'C" strands and, on the back, 
the ABED strands. Hatched circles or squares correspond to missing positions 
according to the IMGT unique numbering. MPZ has two additional positions (46A and 
84A) that interestingly are located at the apex of beta turns and do not disturb the 
general architecture of the domain. 
Swiss-Prot accession numbers: Q16653 for the Homo sapiens MOG protein, 
P13688 for the Homo sapiens CEACAM1 protein, and P25189 for the Homo 
sapiens MPZ protein. IMGT Colliers de Perles were checked with the following 
PDB [42] entries: 1py9_A (Mus musculus MOG [D1]), 1pkq_E (Rattus norvegicus 
MOG [D1]), 1l6z_A (Mus musculus CEACAM1 [D1]), 1neu (Rattus norvegicus 
MPZ [D1]), as the human MOG [D], CEACAM1 [D1] and MPZ [D] have not yet 
been crystallized. 
 
1.1.1 Strands 
  The antiparallel beta strands of the V-LIKE-DOMAIN correspond to the 
conserved regions or framework (FR-IMGT) described in the V-DOMAIN 
[16]. The A strand (A-STRAND, positions 1 to 15) and the B strand (B-
STRAND, positions 16 to 26) with the conserved cysteine (1st-CYS) at 
position 23 correspond to the FR1-IMGT (Table 1). The C strand (C- 
STRAND, positions 39 to 46) with the tryptophan (CONSERVED-TRP) at 
position 41 and the C’ strand (C’-STRAND, positions 47 to 55) correspond to 
FR2-IMGT. The C” strand (C”-STRAND, positions 66 to 74), the D strand (D-
STRAND, positions 75 to 84), the E strand (E-STRAND, positions 85 to 96) 
with a conserved hydrophobic amino acid at position 89 and the F strand (F-
STRAND, positions 97 to 104) with 2nd-CYS at position 104 correspond to 
the FR3-IMGT. The G strand (G-STRAND, positions 118 to 128) corresponds 
to FR4-IMGT (in the IG and TR V-DOMAINs, the G strand is the C-terminal 
part of the J-REGION, with J-PHE or J-TRP 118 and the canonical motif F/W-
G-X-G at positions 118-121). Hatched circles or squares in Figure 3 
correspond to missing positions according to the IMGT unique numbering. For 
example, unoccupied positions 46 and 47 in MOG [D], 10 or 73 in CEACAM1 
[D1] and 10 in MPZ [D], are shown as hatched circles. In the IMGT Protein 
display (Figure 4), unoccupied positions according to the IMGT unique 
numbering are shown by dots. Elodie Duprat et al.  118
1.1.2 Loops 
  The BC, C’C” and FG loops of the V-LIKE-DOMAIN correspond to the 
complementarity-determining regions (CDR-IMGT) described in the IG and TR 
V-DOMAINs [16]. The BC loop (BC-LOOP) comprises positions 27 to 38; the 
longest BC loops have 12 amino acids. For BC loops shorter than 12 amino 
acids, gaps are created at the apex (missing positions, hatched in IMGT Collier 
de Perles (Fig. 3), or not shown in structural data representations). The gaps 
are placed at the apex of the loop with an equal number of codons (or amino 
acids) on both sides if the loop length is an even number, or with one more 
codon (or amino acid) in the left part if it is an odd number. As an example, in 
a BC loop with 9 amino acids (MOG in Figure 3), positions 27 to 31 and 35 to 
38 are present, whereas positions 32 to 34 are missing. The C’C” loop (C’C”-
LOOP) comprises positions 56 to 65. The longest C’C” loops have 10 amino 
 
Table 1. Gaps and additional positions for FG loop 
 
A - Gaps for FG loops less than 13 amino acids 
 
 
 
B - Additional positions for FG loops more than 13 amino acids 
 
 
For FG loops (CDR3-IMGT) more than 13 amino acids, additional 
positions are created between positions 111 and 112 (in bold). In a 
given sequence set with FG loops more than 13 amino acids, gaps are 
created based on the FG loops in the set. As an example, gaps are 
shown by comparison to a 21 amino acid long FG loop. IMGT standardization for IgSF domains    119 
Figure 4 
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Figure 4. IMGT Protein display. (A) Examples of V-DOMAINs and V-LIKE-
DOMAINs (V-set). (B) Examples of C-DOMAINs and C-LIKE-DOMAINs (C-set). #c: 
rearranged cDNA, g: genomic DNA. Amino acids resulting from a splicing with a 
preceding exon are shown between parentheses.  (A) IG and TR V-DOMAINs: VH 
(AB027433, #c IGHV3-30-IGHD4-17-IGHJ3), V-KAPPA (AB022654, #c IGKV1-39-
IGKJ2), V-ALPHA (AK026255, #c TRAV26-1-TRAJ39), V-BETA (AF043183, #c 
TRBV28-TRBD1-TRBJ2-3).  V-LIKE-DOMAINs: MOG [D] (Z48051, g), BTN1A1 
[D1] (U39576, #c, delimitated by homology with MOG [D]), CEACAM1 [D1] 
(AC004785, g, leader delimited according to [43]), MPZ [D] (D14720, g, MPZ [D] 
encoded by EX2 and EX3 with (I)53 resulting from the splicing), CD4 [D1] 
(NT_009759, g, CD4 [D1] encoded by EX2 and EX3 with (G)68 splicing site), CD8A 
[D] (M27161, g), CD8B1 [D] (M17514, partial g, [44]), CEACAM5 [D1] (M59255, g, 
leader delimited according to [45]), CTLA4 [D] (AF411058, g), PIGR [D1] (S43441, 
partial g, limited to EX2; (A) is deduced from S43437), VPREB1 [D] (D86992, g). (B) 
IG and TR C-DOMAINs: CH1 (J00228, g), C-LAMBDA1 (X51755, g), C-ALPHA 
(X02883, g), C-BETA2 (M12888, g). C-LIKE-DOMAINs: KIR2DL2 [D1] (AL133414, 
g), KIR2DL1 [D1] (L41267, #c, delimitated by homology with KIR2DL2 [D1]), 
CEACAM1 [D3] (AC004785, g), VCAM1 [D1] (M73255, g), CD1A [D3] (M22165, 
partial g, limited to EX4; (V) is deduced from M22164), CD3E [D] (M23319, M23320 
and M23321, partial g, limited to EX4, EX5 and EX6, respectively; (G) is deduced 
from M23318), CD4 [D2] (NT_009759, g), CEACAM5 (M59257, partial g, limited to 
EX4; (Y) is deduced from M59256), FCER1A [D1] (L14075, g), FCGR1A [D1] 
(M63832, partial g, limited to EX3; (D) is deduced from M63831), FCGR2A [D1] 
(M90723, partial g, limited to EX3; (A) is deduced from M90722). The accession 
numbers are from IMGT/LIGM-DB (http://imgt.cines.fr) [11,46] for IG and TR, and 
from EMBL/GenBank/DDBJ [47-49] for IgSF other than IG and TR. Beta strands are 
shown by arrows. Dots indicate missing amino acids according to the IMGT unique 
numbering. Putative N-glycosylation sites (N-X-S/T) are underlined.  
(1) Gene names (symbols) for IG and TR are according to the IMGT Nomenclature 
committee (IMGT-NC) [18,19] and the HUGO Nomenclature Committee (HGNC) [50]. 
Full gene designations are the following: MOG: myelin oligodendrocyte glycoprotein; 
BTN1A1: butyrophilin, subfamily 1, member A1; CEACAM1: Carcinoembryonic 
antigen-related cell adhesion molecule 1; MPZ: myelin protein zero (Charcot-Marie-
Tooth neuropathy 1B); CD4: CD4 antigen (p55); CD8A: CD8 antigen, alpha polypeptide 
(p32); CD8B1: CD8 antigen, beta polypeptide 1 (p37); CEACAM5: Carcinoembryonic 
antigen-related cell adhesion molecule 5; CTLA4: cytotoxic T-lymphocyte-associated 
protein 4; PIGR: polymeric immunoglobulin receptor; VPREB1: pre-B lymphocyte gene 
1; IGHG1: Immunoglobulin heavy constant gamma 1; IGLC1: immunoglobulin lambda 
constant 1; TRAC: T cell receptor alpha constant; TRBC2: T cell receptor beta constant 2; 
KIR2DL2: killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 
2; VCAM1: vascular cell adhesion molecule 1; CD1A: CD1A antigen, a polypeptide; 
CD3E: CD3E antigen, epsilon polypeptide (TiT3 complex); CD4: CD4 antigen (p55); 
FCER1A: Fc fragment of IgE, high affinity I, receptor for alpha polypeptide; FCGR1A: 
Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCGR2A: Fc fragment of IgG, 
low affinity IIa, receptor for (CD32). 
(2) Domain name. The C-DOMAINs are designated with the IMGT labels (IMGT 
Scientific  chart,  http://imgt.cines.fr)  The  C-LIKE-DOMAINs    are  designated  by  the IMGT standardization for IgSF domains    121 
Figure legend continued 
 
letter D between brackets with a number, corresponding to the position of the domain 
from the N-terminal end of the protein, and relative to the other domains. There is no 
number if there is a unique C-LIKE-DOMAIN in the chain.  
Amino acid one-letter abbreviation: A (Ala), alanine; C (Cys), cysteine; D (Asp), 
aspartic acid; E (Glu), glutamic acid; F (Phe), phenylalanine; G (Gly), glycine; H (His), 
histidine; I (Ileu), isoleucine; K (Lys), lysine; L (Leu), leucine; M (Met), methionine; N 
(Asn), asparagine; P (Pro), proline; Q (Gln), glutamine; R (Arg), arginine; S (Ser), 
serine; T (Thr), threonine; V (Val), valine; W (Trp), tryptophan;  Y (Tyr), tyrosine.     
 
acids. For C’C” loops shorter than 10 amino acids, gaps are created (missing 
positions, hatched in IMGT Collier de Perles, or not shown in structural data 
representations). As an example, in a C’C” loop with 6 amino acids (MOG and 
MPZ in Figure 3), positions 56 to 58, 63 to 65 are present, whereas positions 59 
to 62 are missing.  The FG loop (FG-LOOP) comprises position 105 to 117. 
These positions correspond to a FG loop of 13 amino acids. For FG loops shorter 
than 13 amino acids, gaps are created from the apex of the loop, in the following 
order 111, 112, 110, 113, 109, 114, etc (Table 1). For FG loops longer than 13 
amino acids (which is rare), additional positions are created, between positions 
111 and 112 at the top of the FG loop (Table 1). 
 
1.1.3 Loop length 
  The loop length (number of codons or amino acids, that is number of 
occupied positions) is a crucial and original concept of IMGT-ONTOLOGY 
[13]. The lengths of the BC, C’C” and FG loops characterize the V-LIKE-
DOMAINs, as the lengths of the CDR1-IMGT, CDR2-IMGT and CDR3-
IMGT characterize the IG and TR V-DOMAINs. Thus, the length of the three 
loops BC, C’C” and FG is shown, in number of codons (or amino acids), into 
brackets and separated by dots (Table 2). For examples: Homo sapiens MOG 
[D] [9.6.9] means that in the human MOG [D] domain, the BC, C’C” and FG 
loops have a length of 9, 6 and 9 codons, respectively; Homo  sapiens 
CEACAM1 [D1] [6.7.10] means that in the human CEACAM1 [D1] domain, 
the BC, C’C” and FG loops have a length of 6, 7 and 10 codons, respectively; 
Homo sapiens MPZ [D] [10.6.11] means that in the human MPZ [D] domain, 
the BC, C’C” and FG loops have a length of 10, 6 and 11 amino acids, 
respectively (Figure 3, Table 2).  
 
1.2 Characteristics of the MOG, CEACAM1  and  MPZ         
V-LIKE-DOMAINs 
1.2.1 Myelin oligodendrocyte glycoprotein 
  The myelin oligodendrocyte glycoprotein (MOG) is a specific component 
of the central nervous system (CNS) localized on the outermost lamellae of Elodie Duprat et al.  122
Table 2. Delimitation of the strands and loops for V-LIKE-DOMAINs 
 
 
 
The delimitations of the strands and loops for the V-LIKE-DOMAINs are identical to 
those of the IG and TR V-DOMAINs. For more details, see [16]. Lengths of the BC, 
C’C” and FG loops are shown within brackets. Blank cells indicate no amino acids. A plus 
sign indicates additional amino acids. Amino acid sequences are shown in Figure 4. 
 
mature myelin [51], and may contribute to myelin maturation and maintenance 
[52] or as a signal to arrest further myelination [53]. MOG may have an unforeseen 
immunological status within the central nervous system, providing for instance 
a rudimentary molecular framework for presentation of pathogens to the 
immune sytem [54]; MOG is a candidate target antigen for autoimmune-mediated 
demyelination, and seems to be implicated in pathogenesis of 
encephalomyelitis and multiple sclerosis, an inflammatory disease of the 
central nervous system [55,56]. The human MOG gene contains 8 exons 
[57]. The N-terminal extracellular V-LIKE-DOMAIN of MOG encoded by 
the exon 2 (EX2) has significant sequence homologies with three non-
myelin proteins: Homo sapiens butyrophilin (BTN1A1; subfamily 1, 
member A1) expressed in the mammary gland during lactation and 
facilitating the interaction between cytoplasmic lipid droplets and the 
apical membrane [58], Gallus gallus B-G antigen encoded by a gene 
mapping to the major histocompatibility complex [59], and Gallus gallus 
BEN adhesion glycoprotein expressed on the epithelial cells of the bursa of 
Fabricius and on various neuronal subsets during chicken embryonic 
development [60]. The IMGT unique numbering  allows  us  to  compare     
H. sapiens MOG [D] and H. sapiens BTN1A1 [D1] and to describe divergent 
positions (Figure 3). The MOG and BTN1A1 genes are colocalized near IMGT standardization for IgSF domains    123 
the human MHC on chromosome 6p21.3-p22 [61]. Two motifs highly 
homologous to consensus sequences found in glial promoters of proteolipid 
protein (PLP), protein zero (MPZ), myelin basic protein (MBP), and mouse 
MOG were also found in human MOG [62]. The H. sapiens MOG V-
LIKE-DOMAIN has not yet been crystallized, but interestingly PDB has an 
entry for the Rattus norvegicus MOG V-LIKE-DOMAIN in complex with 
Fab fragment of Mus musculus antibody anti-MOG 8-18C5 (1pkq), that 
allows to identify the MOG FG loop as an important epitope [63,64], and 
to  confirm  the  N-glycosylated  site  in  N31  (BC-LOOP)  (conserved  in        
H. sapiens MOG sequence, Figure 3); the MOG FG loop may be 
implicated in autoimmune recognition [63]. 
 
1.2.2 Carcinoembryonic antigen-related cell adhesion molecule 1 
  Members of the CEA family consist of a single N-terminal V-LIKE-
DOMAIN, followed by a variable number of C-LIKE-DOMAINs. Based 
on sequence similarity and functional characteristics, the CEA family has 
been subdivided into the CEA subfamily and the pregnancy-specific 
glycoprotein (PSG) subfamily [65]. Members of the CEA subfamily are 
anchored in the cell membrane, whereas all of the PSGs appear to be 
secreted; however, the genes in the CEA and PSG subfamilies have a similar 
gene structure and organization. The carcinoembryonic antigen-related cell 
adhesion molecule 1 (CEACAM1, or biliary glycoprotein BGP) consists of a 
single N-terminal V-LIKE-DOMAIN followed by 3 C-LIKE-DOMAINs, 
and is expressed in cells of epithelial and myeloid origin [43]. In 
granulocytes, CEACAM1 is a main antigen of the CD66 cluster of 
differentiation antigens that mediate the binding to endothelial E-selectin. 
The loss or reduced expression of the CEACAM1 adhesion molecule is a 
major event in colorectal carcinogenesis [66]. 
 
1.2.3 Myelin protein zero 
  The myelin protein zero (MPZ or P0) gene is localized at 1q21.3-q23, 
about 130 kb of the FCGR2A gene [67]. MPZ is the major structural protein of 
peripheral myelin, accounting for more than 50% of the protein present in the 
sheath of peripheral nerves. Expression of the MPZ gene is restricted to 
Schwann cells; MPZ is not found in the CNS. MPZ corresponds to an integral 
membrane glycoprotein of 28 kD, and is thought to link adjacent lamellae and 
thereby stabilize the myelin assembly. The V-LIKE-DOMAIN [D] that is 
encoded by EX2 and EX3, plays a significant role in myelin membrane 
adhesion. Several mutations in the MPZ V-LIKE-DOMAIN are associated 
with the autosomal dominant form of Charcot-Marie-Tooth disease type 1, 
which is characterized by progressive slowing of nerve conduction and 
hypertrophy of Schwann cells: the amino acid changes D68>E (C’’-STRAND) Elodie Duprat et al.  124
and K74>E (C’’-STRAND, near the C’’D-TURN) are independently 
implicated in Charcot-Marie-Tooth disease type 1B (CMT1B) [68], whereas 
all affected members of another CTM1B family had a 3-bp deletion in EX2 
causing loss of the S38 (S38>del; BC-LOOP) [69]. S38>C was found in a 7-
year-old boy (heterozygous for the mutation, which was absent in the parents 
and in 100 unrelated healthy controls) with delayed motor development, 
hypotonia, muscle weakness, and sensory disturbance thought to be typical of 
Dejerine-Sottas syndrome, or hereditary motor and sensory neuropathy type III 
(HMSN3) [68,70]. Partial symptom relief with corticosteroid treatment was 
reported [71] in a patient with demyelinating CMT1B and a heterozygous 
R76>H mutation (D-STRAND, near the C’’D-TURN). Although this response 
is rare in such patients, poor myelin compaction by the MPZ protein, caused 
by the mutation, may have allowed circulating immune elements access to 
normally sequestered endoneurial components, thus accounting for the 
response to corticosteroid treatment [71] (OMIM: 159440). 
 
2. IMGT Colliers de Perles for C-LIKE-DOMAIN 
  The IMGT Colliers de Perles for C-LIKE-DOMAIN is based on the IMGT 
unique numbering for C-DOMAIN [17]. This numbering is itself derived from 
the IMGT unique numbering for V-DOMAIN [14-16]. Indeed, the sandwich 
beta sheet of the C-set (C-DOMAIN and C-LIKE-DOMAIN) has the same 
topology and 3D structure than the V-set (V-DOMAIN and V-LIKE-DOMAIN), 
but they differ by the number of strands (Figure 1). The C-LIKE-DOMAIN, as 
the IG and TR C-DOMAIN, is made of seven beta strands linked by beta turns or 
loops, and arranged so that four strands form one sheet and three strands form a 
second sheet. A characteristic CD transversal strand links the two sheets; 
depending from the CD length, the D strand is in the first or second sheet (shown 
by an arrow in Figure 1). As shown in Table 3, the IMGT unique numbering for 
the C-LIKE-DOMAIN follows the same rules as those of the C-DOMAIN [17]. 
 
2.1. Strands, loops and turns of the C-LIKE-DOMAINs 
  Three examples of C-LIKE-DOMAIN are shown in Figure 5: the killer 
cell immunoglobulin-like receptor KIR2DL2 (two domains, long cytoplasmic 
tail, 2) [D1], the carcinoembryonic antigen-related cell adhesion molecule 1 
(CEACAM1) [D3] and the vascular cell adhesion molecule 1 (VCAM1) [D1]. 
 
2.1.1 Strands 
  The A strand (A-STRAND, positions 1 to 15) and the B strand (B-
STRAND, positions 16 to 26, with the 1st-CYS at position 23) are similar to 
those of the V-DOMAIN and V-LIKE-DOMAIN [16,17]. The C strand (C-
STRAND, positions 39 to 45, with the CONSERVED-TRP at position 41) and 
the D strand (D-STRAND, positions 77 to 84) are shorter of one position and IMGT standardization for IgSF domains    125 
Table 3. Delimitation of the strands and loops for C-LIKE-DOMAINs 
 
 
 
Delimitations of the strands and loops for C-LIKE-DOMAINs are identical to those of 
the IG and TR C-DOMAINs. For more details, see [17]. A plus sign indicates 
additional amino acids. KIR2DL2 [D1] has one additional position in 15.1, whereas 
15.2 and 15.3 are unoccupied. VCAM1 [D1] has four additional positions 84.1, 84.2, 
85.2 and 85.1. Amino acid sequences are shown in Figure 4. 
 
two positions, respectively, compared to the V-DOMAIN and V-LIKE-
DOMAIN. As previously described [17], the C' and C" strands are missing 
and are replaced by the characteristic transversal CD strand (CD-STRAND, 
positions 45.1 to 45.7). The E strand (E-STRAND, positions 85 to 96, with a 
conserved hydrophobic amino acid at position 89), the F strand (F-STRAND, 
positions 97 to 104, with the 2nd-CYS at position 104) and the G strand (G-
STRAND, positions 118 to 128, with a conserved hydrophobic amino acid at 
position 121) are similar to those of the V-DOMAIN and V-LIKE-
DOMAIN. 
 
2.1.2 Loops 
  The BC loop (BC-LOOP) comprises positions 27 to 36; the longest BC 
loops have 10 amino acids, instead of 12 amino acids in the V-DOMAIN and V-
LIKE-DOMAIN. For BC loops shorter than 10 amino acids, gaps are created 
from the apex in the following order 32, 31, 33, 30, 34, etc. As an example, in a 
BC loop with 5 amino acids (KIR2DL2 [D1] in Figure 5), positions 27 to 29 and 
35 and 36 are present, whereas positions 30 to 34 are missing. The FG loop (FG-
LOOP) comprises positions 105 to 117 and is similar to that of the V-DOMAIN 
and V-LIKE-DOMAIN. These positions correspond to a FG loop of 13 amino 
acids. Gaps for FG loops shorter than 13 amino acids and additional positions 
for FG loops longer than 13 amino acids, are created following the same rules 
as those of the V-DOMAIN and V-LIKE-DOMAIN (Table 1). As examples, 
CEACAM1 [D3] has a FG loop of 13 amino acids, VCAM1 [D] has a FG loop of  Elodie Duprat et al.  126
Figure 5 
 
A. Homo sapiens KIR2DL2 [D1] C-LIKE-DOMAIN 
           
 
B. Homo sapiens CEACAM1 [D3] C-LIKE-DOMAIN 
 
         
 
C. Homo sapiens VCAM1 [D1] C-LIKE-DOMAIN 
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Figure 5. IMGT Colliers de Perles of C-LIKE-DOMAINs on one and two layers. (A) 
Homo sapiens KIR2DL2 [D1], (B) Homo sapiens CEACAM1 [D3], (C) Homo sapiens 
VCAM1 [D1]. Amino acids are shown in the one-letter abbreviation. Position at which 
hydrophobic amino acids (hydropathy index with positive value: I, V, L, F, C, M, A) 
and tryptophan (W) are found in more than 50% of analysed sequences are shown in 
blue. All proline (P) are shown in yellow. The positions 26, 39 and 104 are shown in 
squares by homology with the corresponding positions in the V-set (V-DOMAINs and 
V-LIKE-DOMAINs). Positions 45 and 77 which delimit the characteristic CD strand of 
the C-set (C-DOMAINs and C-LIKE-DOMAINs), and position 118 which corresponds 
structurally to J-PHE or J-TRP of the IG and TR J-REGION [16,17], are also shown in 
squares. Hatched circles correspond to missing positions according to the IMGT unique 
numbering for C-DOMAINs and C-LIKE-DOMAINs. Arrows indicate the direction of 
the beta strands and their different designations in 3D structures (from IMGT 
Repertoire, http://imgt.cines.fr). The IMGT Colliers de Perles on two layers (on the 
right hand) show, on the forefront, the GFC strands and, on the back, the ABE strands. 
Swiss-Prot accession numbers: P43627 for the H. sapiens KIR2DL2 protein, P13688 
for the H. sapiens CEACAM1 protein, and P19320 for the H. sapiens VCAM1 protein. 
T h e  I M G T  C o l l i e r s  d e  P e r l e s  w e r e  c h e c k e d with the following PDB [42] entries: 
1efx_D (H. sapiens KIR2DL2 [D1]), 1l6z_A (Mus musculus CEACAM1 [D4], 
sequence similar to the H. sapiens CEACAM1 [D3]; no available 3D structure of the H. 
sapiens CEACAM1 [D3]), 1vsc_A (H. sapiens VCAM1 [D1]).   
 
9 amino acids (with four gaps 110 to 113), whereas KIR2DL2 [D1] has a FG 
loop of 14 amino acids with the additional position 112.1 (Figure 5). 
 
2.1.3 Turns 
  The AB turn (AB-TURN) corresponds to additional positions 15.1, 15.2 and 
15.3; the longest AB turns have 3 amino acids. For AB turns shorter than 3 amino 
acids, gaps are created (missing positions, hatched in the IMGT Colliers de Perles 
(Fig. 5), or not shown in structural data representations) in an ordinal manner. As 
an example, KIR2DL2 [D1] has one additional position in 15.1, whereas 15.2 and 
15.3 are unoccupied. The DE turn (DE-TURN) comprises positions 84.1 to 84.7 
and 85.7 to 85.1, corresponding to 14 amino acids. For DE turns shorter than 14 
amino acids, gaps are created in the following order: 85.1, 84.1, 85.2, 84.2, 85.3, 
84.3, etc. As an example, VCAM1 [D1] has four additional positions 84.1, 84.2, 
85.2 and 85.1. The EF turn (EF-TURN) corresponds to additional positions 96.1 
and 96.2 when present, corresponding to 2 amino acids. For EF turns shorter than 2 
amino acids, gaps are created in the following order: 96.2, 96.1.  
 
2.2 Characteristics of the KIR2DL2 and VCAM1 C-LIKE-
DOMAINs 
2.2.1 KIR2DL2 
  The second killer cell immunoglobulin-like receptor with two domains and 
a long cytoplasmic tail (KIR2DL2) corresponds to a 348 amino acid type I Elodie Duprat et al.  128
transmembrane protein [72,73]. Sequence analysis revealed a structure similar to 
that described for KIR2DL1, with two extracellular C-LIKE-DOMAINs ([D1] and 
[D2]), a transmembrane domain, and a long cytoplasmic tail with two 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs). According to the IMGT 
unique numbering, divergent positions between KIR2DL2 and KIR2DL1 are 
localized in the A-STRAND (R12>P), BC-LOOP (R28>M), CD-STRAND 
(K45.1>M, K45.3>N), D-STRAND (H78>R), E-STRAND (G92>S, P93>R, 
M95>T), FG-LOOP (L114>V) and G-STRAND (T126>I). KIR2D receptors are 
divided into two families based on their specificities for different HLA-C allotypes: 
the KIR2DL1 is specific for HLA-Cw2, 4, 6 and 15, whereas KIR2DL2 is specific 
for HLA-Cw1, 3, 7 and 8. KIR2DL2/HLA-Cw3 and KIR2DL1/HLA-Cw4 share a 
common binding mode [74], and a single K45.1>M amino acid change between 
KIR2DL2 and KIR2DL1 is sufficient to switch allotype specificity [75]. 
 
2.2.2 VCAM1 
  The vascular cell adhesion molecule 1 (VCAM1) is expressed by cytokine-
activated endothelium, binds leukocyte integrins and is involved in inflammatory 
and immune functions [76,77]. This type I membrane protein mediates 
leukocyte-endothelial cell adhesion and signal transduction, and may play a role 
in the development of arteriosclerosis and rheumatoid arthritis. VCAM1 is 
present in single copy in the human genome and contains 9 exons spanning 
about 25 kb of DNA. At least 2 different VCAM1 precursors can be generated 
from the human gene as a result of alternative mRNA splicing events, which 
include or exclude exon 5 [76]. The major form is composed of seven C-LIKE-
DOMAINs, of which domains [D1], [D2] and [D3] are strikingly homologous in 
both structure and function to [D4], [D5] and [D6] domains [77,78]. The 
functionally important [D1] domain essential for binding to the integrin ligand 
contains two rather than one pair of cysteine residues; 1st-CYS 23 and 2nd-CYS 
104 correspond to the core disulfide bond of the domain between the B and the F 
strands, whereas C28 and C108 form an additional disulfide bond between the 
BC and the FG loops. Mutagenesis studies directed at [D1] have identified two 
sets of residues involved in binding [79,80]. According to the IMGT unique 
numbering, these amino acids are D45.1 and P45.3 (CD-STRAND), and G95 
(EF-LOOP). P45.3 appears to be particularly important, since its limited 
conformational freedom brings the Cα atoms of T43 (C-STRAND) and L45.4 
(CD-STRAND) within 7 Å of each other [81]. G95 is located in the EF loop, in 
close proximity of the CD loop (Figure 5). It might interact directly with the 
integrin ligand, or it might play an indirect role by stabilizing the structure of the 
CD loop. There is an extensive network of hydrogen bonds between the CD and 
EF loops, some of which involve the side chain of H100. A cyclic peptide that 
mimics the CD loop inhibits binding of a4b1 integrin-bearing cells to VCAM1. 
[D2] may have a role in ligand binding [81]. IMGT standardization for IgSF domains    129 
3. IMGT Protein displays 
  A comparison between the V-set (V-DOMAIN and V-LIKE-DOMAIN) 
and C-set (C-DOMAIN and C-LIKE-DOMAIN) domains is shown in the 
IMGT Protein display (Figure 4). Amino acid positions shown on the upper 
line in the IMGT Protein displays correspond to equivalent positions in both 
sets, whereas amino acid positions on the lower lines are characteristic of each 
set. Sixty-five positions are structurally equivalent between the V-set and the 
C-set, when the strands A to G are compared. They comprise: positions 1-15 
(A strand), 16-26 (B strand), 39-45 (C strand), 77-84 (D strand), 85-96 (E 
strand), 97-104 (F strand), 118 up to at least 121 (G strand). Thirty-five 
positions are characteristic of the C-set numbering. The positions of these 
additional positions compared to the V-set numbering are designated by a 
number followed by a dot and a number: 1.1 to 1.9 (at the N-terminal end), 
15.1 to 15.3 (at the AB turn, for example 15.1 in KIR2DL2 [D1], KIR2DL1 
[D1] and VCAM1 [D1]), 45.1 to 45.7 (that represent the CD transversal 
strand), 84.1 to 84.7, 85.7 to 85.1 (at the DE loop; these positions correspond 
to longer antiparallel D and E strands in the C-set), 96.1 and 96.2 (at the EF 
turn). Thirty-three positions are missing in the C-set, compared to the V-set. 
Two of these positions (37 and 38) are missing in the BC loop. The thirty-one 
other positions (46 to 76) correspond to the two C' and C'' strands and to the 
C’C” loop (CDR2-IMGT), present in the V-set but absent in the C-set. 
Positions 45.1 to 45.7 are structurally different between the C-set and the V-set 
[17]. Indeed, as described above, these positions represent a transversal strand 
between C and D in the C-set, whereas there are two additional C’ and C” 
strands in the V-set. 
  In Figure 4, amino acids which result from the splicing with the preceding 
exon are shown within parentheses. Indeed, the exact delimitations of the V-
LIKE-DOMAINs and C-LIKE-DOMAINs can be usually identified when 
genomic sequences are available [35]. Each domain shown in Figure 4, except 
CD4 [D1] and MPZ [D], is encoded by a unique exon.  
 
4. IMGT Alignments of alleles 
  The IMGT unique numbering allows a standardized description of allele 
polymorphisms and mutations of the V-LIKE-DOMAINs and C-LIKE-
DOMAINs. Alleles from the human FCGR3B have recently been described 
based on these criteria [37]. The mutations and allelic polymorphisms are 
described per domain and by comparison to the allele *01 from the IMGT 
reference directory. Based on these criteria, IMGT ‘Alignments of alleles’ 
[11,12] allow a standardized display according to the IMGT unique numbering 
and with the strand and loop delimitations [35]. Other features of the amino 
acid sequences, such as positions of the N-glycosylation site and amino acids 
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Conclusion 
  The IMGT unique numbering gives insight in the structural configuration of 
the V-LIKE-DOMAINs and C-LIKE-DOMAINs belonging to the human IgSF 
proteins, but also opens interesting views on the evolution of the sequences of 
the V-set and C-set [16,17]. Indeed, the IMGT unique numbering can be applied 
to any IgSF V-set or C-set domain. In the absence of available 3D structures, the 
V-LIKE-DOMAIN and C-LIKE-DOMAIN IMGT Colliers de Perles are 
particulary useful for comparison with domains of known 3D structures.  
  The IMGT unique numbering has many advantages. It allows an easy 
comparison between sequences coding the V-LIKE-DOMAINs and C-LIKE-
DOMAINs, whatever the IgSF protein, the chain type or the species. It has 
allowed to show that the distinction between C1 and C2 becomes unnecessary 
(discussed in [17]). It allows, by comparison with genomic sequences, to delimit 
precisely the V-LIKE-DOMAINs and C-LIKE-DOMAINs. Moreover, it allows 
to determine the lengths of the BC, C'C" and FG loops of the V-LIKE-
DOMAINs and those of the BC loop, CD transversal strand and FG loop of the 
C-LIKE-DOMAINs. The strand and loop lengths (number of codons or of amino 
acids, that is number of occupied positions) become crucial information 
characterizing the V-set and C-set domains, and the corresponding genes, 
cDNAs and proteins [16,17]. IMGT quality assessment of the data is performed 
at both the sequence level and 3D structure level. Indeed, the delimitations of the 
domains are based on the location of the splicing sites in genomic sequences. 
The IMGT unique numbering has allowed standardized analysis and 
representations of nucleotide and amino acid sequences (Tables of FR and CDR 
lengths, Tables of alleles, Alignments of alleles, IMGT Protein displays, IMGT 
Colliers de Perles, 3D structures). The IMGT unique numbering represents, 
therefore, a major step forward in analysing and comparing the structure and 
evolution of the proteins belonging to the immunoglobulin superfamily. 
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